IMP761 is a first-in-class agonist LAG-3 antibody designed to restore balance to the immune system by enhancing the "brake” ...

A far shorter, simpler, and less toxic treatment protocol for patients with triple-negative breast cancer produced outcomes ...

Aethlon announces first patient enrolled and treated with the Hemopurifier at the Cancer Clinical Trial Unit, CALHN, Royal Adelaide Hospital: San Diego Friday, January 31, 2025, 1 ...

Bone metastases are at the center of advanced prostate cancer care, with over 90% of patients with metastatic prostate cancer expected to have bone involvement. 1 These metastatic ...

Kazia Therapeutics is at the forefront of developing cutting-edge cancer therapies, with a key focus on brain cancer and aggressive tumor types like triple-negative breast cancer. The company’s ...

The Phase III HYPERION trial was stopped early after strong positive interim results from the ZENITH trial demonstrated the efficacy of Winrevair (sotatercept-csrk) in treating pulmonary arterial ...

DelveInsight’s Advanced Cervical Cancer pipeline report depicts a robust space with 70+ active players working to develop 75+ ...

A new study has found a way to treat patients with triple-negative breast cancer using a shorter and less toxic treatment plan while achieving similar results to the current standard. The study, ...

Data presented at the ASCO Gastrointestinal Cancers Symposium showed the regimen may be a new option, but it comes with more treatment and financial toxicity.